I-Mab (NASDAQ:NBP) SVP Sells $13,766.36 in Stock

I-Mab (NASDAQ:NBP) SVP Cong Claire Xu sold 3,494 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $3.94, for a total transaction of $13,766.36. Following the completion of the sale, the senior vice president directly owned 290,154 shares of the company’s stock, valued at $1,143,206.76. The trade was a 1.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

I-Mab Price Performance

Shares of NBP opened at $1.80 on Friday. The stock has a 50 day simple moving average of $2.22. I-Mab has a fifty-two week low of $1.63 and a fifty-two week high of $6.79. The stock has a market cap of $208.17 million, a PE ratio of -5.00 and a beta of 1.47.

I-Mab (NASDAQ:NBP) last posted its earnings results on Wednesday, April 8th. The company reported ($0.30) EPS for the quarter. On average, equities analysts expect that I-Mab will post -0.56 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NBP has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price target on shares of I-Mab in a report on Wednesday, April 8th. Wall Street Zen cut shares of I-Mab from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Finally, Weiss Ratings raised shares of I-Mab from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $9.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in I-Mab stock. Brooklyn Investment Group bought a new position in shares of I-Mab (NASDAQ:NBP) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 12,715 shares of the company’s stock, valued at approximately $51,000. Institutional investors and hedge funds own 38.38% of the company’s stock.

I-Mab Company Profile

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.